Rare neuroendocrine carcinoma of the gall bladder: Coincidental occurrence of an endometrioid ovarian adenocarcinoma;Seltenes neuroendokrines karzinom der gallenblase: Abgrenzung zur metachronen koinzidenz mit einem endometrioiden adenokarzinom des ovars

Deutsche Medizinische Wochenschrift

Volumn 134, Issue 1-2, 2009, Pages 19-22

  Petersen, M ^a   Meyer, F ^a   Kalinski, T ^a   Bischoff, J ^a   Bohr, U R M ^a   Lippert, H ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

Author keywords

Demografic changes; Immunhistochemistry; Neuroendocrine carcinoma of the gall bladder; Ovarian carcinoma; Second neoplasias

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; CHROMOGRANIN A; CISPLATIN; ETOPOSIDE; INTERLEUKIN 5 RECEPTOR ALPHA; SYNAPTOPHYSIN;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; CHOLECYSTECTOMY; CHOLELITHIASIS; FEMALE; GALLBLADDER CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; LAPAROTOMY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS; NEUROENDOCRINE TUMOR; OVARY ADENOCARCINOMA; PROTEIN EXPRESSION; CARCINOMA; ENDOMETRIOID CARCINOMA; GALLBLADDER TUMOR; IMMUNOHISTOCHEMISTRY; OVARY TUMOR; PATHOLOGY; SECOND CANCER; TUMOR RECURRENCE;

AGED; CARCINOMA, ENDOMETRIOID; CARCINOMA, NEUROENDOCRINE; CHEMOTHERAPY, ADJUVANT; CHOLECYSTECTOMY, LAPAROSCOPIC; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; OVARIAN NEOPLASMS;

EID: 58149359273     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0028-1105884     Document Type: Article

References (11)

1. Heitz PU, Roth J, Zuber C, Komminoth P. Markers for neural and endocrine cells in pathology:In: Gratzl M, Langley L (Hrsg). Markers for neural and endocrine cells. Weinheim: VCH, 1991: 203-216
2. Joel W. Karzinoidtumor der Gallenblase. Zentralbl Allg Pathol 1929; 46: 1-4
3. Modlin IM, Shapiro MD, Kidd M. An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg 2005; 29 (1): 92-101 (Pubitemid 40576497)
4. Nishigami T, Yamada M, Nakasho K, Yamamura M, Satomi M, Uematsu K, Ri G, Mizuta T, Fukumoto H. Carcinoid Tumor of the Gall Bladder. Int Med 1996; 35: 953-956
5. Oberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 2002; 14: 38-45 (Pubitemid 34072962)
6. Psathakis D, Wenk H, Müller G, Bruch HP. Primary Carcinoid Tumor of the Gallbladder. Hepatogastroenterology 1996; 43: 167-168
7. Ries LA, Wingo PA, Miller DS, Howe HL, Weir HK, Rosenberg HM, Vernon SW, Cronin K, Edwards BK. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 2000; 88: 2398-2424
8. Rindi G, Klöppel G, Alhman H et al. Frascati Consensus Conference participants; European Neuroendocrine Tumor Society (ENETS). TNM staging of foregut (neuro) endocrine tumors: a consens proposal including a grading systems. Virchows Arch 2006; 449: 395-401
9. Schyra D, Ehninger G, Breidert M. Diagnostik und Therapie neuroendokriner Tumoren. Ärzteblatt Sachsen 2003; 3: 100-103
10. Skirnisdottir I, Scorbe B. Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-iV) epithelial ovarian carcinoma. Int J Oncol 2007; 30: 727-734
11. Solcia E, Klöppel G, Sobin LH (In collaboration with 9 pathologists from 4 countries) . Histological typing of endocrine tumours. 2nd Edition, WHO international histological classification of tumours. Berlin: Springer, 2000